Global Oligonucleotide Drugs (ONs) Market Growth 2022-2028
Nucleic acid medicines utilize nucleic acid, which refer to substances such as DNA and RNA that control genetic information, as drugs. These allow targeting of molecules such as mRNA and miRNA that cannot be targeted with traditional low molecular weight drugs and antibody medicines, and there is a great expectation for these drugs as next generation pharmaceuticals. Active research is being conducted globally as it is expected to lead to the creation of drugs which were previously intractable.
The global market for Oligonucleotide Drugs (ONs) is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Oligonucleotide Drugs (ONs) market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Oligonucleotide Drugs (ONs) market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Oligonucleotide Drugs (ONs) market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Oligonucleotide Drugs (ONs) market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Oligonucleotide Drugs (ONs) players cover Novartis, Ionis, Nippon Shinyaku, Alnylam and Sarepta Therapeutics, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Oligonucleotide Drugs (ONs) market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Oligonucleotide Drugs (ONs) market, with both quantitative and qualitative data, to help readers understand how the Oligonucleotide Drugs (ONs) market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.
Market Segmentation:
The study segments the Oligonucleotide Drugs (ONs) market and forecasts the market size by Type (ASO, siRNA and Other), by Application (Cardiovascular Diseases, Hepatitis B, Hypertension and Other), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
ASO
siRNA
Other
Segmentation by application
Cardiovascular Diseases
Hepatitis B
Hypertension
Other
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Novartis
Ionis
Nippon Shinyaku
Alnylam
Sarepta Therapeutics
MiNA Therapeutics
BioNTech
Moderna
Chapter Introduction
Chapter 1: Scope of Oligonucleotide Drugs (ONs), Research Methodology, etc.
Chapter 2: Executive Summary, global Oligonucleotide Drugs (ONs) market size (sales and revenue) and CAGR, Oligonucleotide Drugs (ONs) market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Oligonucleotide Drugs (ONs) sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Oligonucleotide Drugs (ONs) sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Oligonucleotide Drugs (ONs) market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Novartis, Ionis, Nippon Shinyaku, Alnylam, Sarepta Therapeutics, MiNA Therapeutics, BioNTech and Moderna, etc.
Chapter 14: Research Findings and Conclusion
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Oligonucleotide Drugs (ONs) Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Oligonucleotide Drugs (ONs) by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Oligonucleotide Drugs (ONs) by Country/Region, 2017, 2022 & 2028
2.2 Oligonucleotide Drugs (ONs) Segment by Type
2.2.1 ASO
2.2.2 siRNA
2.2.3 Other
2.3 Oligonucleotide Drugs (ONs) Sales by Type
2.3.1 Global Oligonucleotide Drugs (ONs) Sales Market Share by Type (2017-2022)
2.3.2 Global Oligonucleotide Drugs (ONs) Revenue and Market Share by Type (2017-2022)
2.3.3 Global Oligonucleotide Drugs (ONs) Sale Price by Type (2017-2022)
2.4 Oligonucleotide Drugs (ONs) Segment by Application
2.4.1 Cardiovascular Diseases
2.4.2 Hepatitis B
2.4.3 Hypertension
2.4.4 Other
2.5 Oligonucleotide Drugs (ONs) Sales by Application
2.5.1 Global Oligonucleotide Drugs (ONs) Sale Market Share by Application (2017-2022)
2.5.2 Global Oligonucleotide Drugs (ONs) Revenue and Market Share by Application (2017-2022)
2.5.3 Global Oligonucleotide Drugs (ONs) Sale Price by Application (2017-2022)
3 Global Oligonucleotide Drugs (ONs) by Company
3.1 Global Oligonucleotide Drugs (ONs) Breakdown Data by Company
3.1.1 Global Oligonucleotide Drugs (ONs) Annual Sales by Company (2020-2022)
3.1.2 Global Oligonucleotide Drugs (ONs) Sales Market Share by Company (2020-2022)
3.2 Global Oligonucleotide Drugs (ONs) Annual Revenue by Company (2020-2022)
3.2.1 Global Oligonucleotide Drugs (ONs) Revenue by Company (2020-2022)
3.2.2 Global Oligonucleotide Drugs (ONs) Revenue Market Share by Company (2020-2022)
3.3 Global Oligonucleotide Drugs (ONs) Sale Price by Company
3.4 Key Manufacturers Oligonucleotide Drugs (ONs) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Oligonucleotide Drugs (ONs) Product Location Distribution
3.4.2 Players Oligonucleotide Drugs (ONs) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Oligonucleotide Drugs (ONs) by Geographic Region
4.1 World Historic Oligonucleotide Drugs (ONs) Market Size by Geographic Region (2017-2022)
4.1.1 Global Oligonucleotide Drugs (ONs) Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Oligonucleotide Drugs (ONs) Annual Revenue by Geographic Region
4.2 World Historic Oligonucleotide Drugs (ONs) Market Size by Country/Region (2017-2022)
4.2.1 Global Oligonucleotide Drugs (ONs) Annual Sales by Country/Region (2017-2022)
4.2.2 Global Oligonucleotide Drugs (ONs) Annual Revenue by Country/Region
4.3 Americas Oligonucleotide Drugs (ONs) Sales Growth
4.4 APAC Oligonucleotide Drugs (ONs) Sales Growth
4.5 Europe Oligonucleotide Drugs (ONs) Sales Growth
4.6 Middle East & Africa Oligonucleotide Drugs (ONs) Sales Growth
5 Americas
5.1 Americas Oligonucleotide Drugs (ONs) Sales by Country
5.1.1 Americas Oligonucleotide Drugs (ONs) Sales by Country (2017-2022)
5.1.2 Americas Oligonucleotide Drugs (ONs) Revenue by Country (2017-2022)
5.2 Americas Oligonucleotide Drugs (ONs) Sales by Type
5.3 Americas Oligonucleotide Drugs (ONs) Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oligonucleotide Drugs (ONs) Sales by Region
6.1.1 APAC Oligonucleotide Drugs (ONs) Sales by Region (2017-2022)
6.1.2 APAC Oligonucleotide Drugs (ONs) Revenue by Region (2017-2022)
6.2 APAC Oligonucleotide Drugs (ONs) Sales by Type
6.3 APAC Oligonucleotide Drugs (ONs) Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Oligonucleotide Drugs (ONs) by Country
7.1.1 Europe Oligonucleotide Drugs (ONs) Sales by Country (2017-2022)
7.1.2 Europe Oligonucleotide Drugs (ONs) Revenue by Country (2017-2022)
7.2 Europe Oligonucleotide Drugs (ONs) Sales by Type
7.3 Europe Oligonucleotide Drugs (ONs) Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Oligonucleotide Drugs (ONs) by Country
8.1.1 Middle East & Africa Oligonucleotide Drugs (ONs) Sales by Country (2017-2022)
8.1.2 Middle East & Africa Oligonucleotide Drugs (ONs) Revenue by Country (2017-2022)
8.2 Middle East & Africa Oligonucleotide Drugs (ONs) Sales by Type
8.3 Middle East & Africa Oligonucleotide Drugs (ONs) Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Oligonucleotide Drugs (ONs)
10.3 Manufacturing Process Analysis of Oligonucleotide Drugs (ONs)
10.4 Industry Chain Structure of Oligonucleotide Drugs (ONs)
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Oligonucleotide Drugs (ONs) Distributors
11.3 Oligonucleotide Drugs (ONs) Customer
12 World Forecast Review for Oligonucleotide Drugs (ONs) by Geographic Region
12.1 Global Oligonucleotide Drugs (ONs) Market Size Forecast by Region
12.1.1 Global Oligonucleotide Drugs (ONs) Forecast by Region (2023-2028)
12.1.2 Global Oligonucleotide Drugs (ONs) Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Oligonucleotide Drugs (ONs) Forecast by Type
12.7 Global Oligonucleotide Drugs (ONs) Forecast by Application
13 Key Players Analysis
13.1 Novartis
13.1.1 Novartis Company Information
13.1.2 Novartis Oligonucleotide Drugs (ONs) Product Offered
13.1.3 Novartis Oligonucleotide Drugs (ONs) Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Novartis Main Business Overview
13.1.5 Novartis Latest Developments
13.2 Ionis
13.2.1 Ionis Company Information
13.2.2 Ionis Oligonucleotide Drugs (ONs) Product Offered
13.2.3 Ionis Oligonucleotide Drugs (ONs) Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Ionis Main Business Overview
13.2.5 Ionis Latest Developments
13.3 Nippon Shinyaku
13.3.1 Nippon Shinyaku Company Information
13.3.2 Nippon Shinyaku Oligonucleotide Drugs (ONs) Product Offered
13.3.3 Nippon Shinyaku Oligonucleotide Drugs (ONs) Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Nippon Shinyaku Main Business Overview
13.3.5 Nippon Shinyaku Latest Developments
13.4 Alnylam
13.4.1 Alnylam Company Information
13.4.2 Alnylam Oligonucleotide Drugs (ONs) Product Offered
13.4.3 Alnylam Oligonucleotide Drugs (ONs) Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Alnylam Main Business Overview
13.4.5 Alnylam Latest Developments
13.5 Sarepta Therapeutics
13.5.1 Sarepta Therapeutics Company Information
13.5.2 Sarepta Therapeutics Oligonucleotide Drugs (ONs) Product Offered
13.5.3 Sarepta Therapeutics Oligonucleotide Drugs (ONs) Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Sarepta Therapeutics Main Business Overview
13.5.5 Sarepta Therapeutics Latest Developments
13.6 MiNA Therapeutics
13.6.1 MiNA Therapeutics Company Information
13.6.2 MiNA Therapeutics Oligonucleotide Drugs (ONs) Product Offered
13.6.3 MiNA Therapeutics Oligonucleotide Drugs (ONs) Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 MiNA Therapeutics Main Business Overview
13.6.5 MiNA Therapeutics Latest Developments
13.7 BioNTech
13.7.1 BioNTech Company Information
13.7.2 BioNTech Oligonucleotide Drugs (ONs) Product Offered
13.7.3 BioNTech Oligonucleotide Drugs (ONs) Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 BioNTech Main Business Overview
13.7.5 BioNTech Latest Developments
13.8 Moderna
13.8.1 Moderna Company Information
13.8.2 Moderna Oligonucleotide Drugs (ONs) Product Offered
13.8.3 Moderna Oligonucleotide Drugs (ONs) Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Moderna Main Business Overview
13.8.5 Moderna Latest Developments
14 Research Findings and Conclusion
Tables and Figures
List of Tables
Table 1. Oligonucleotide Drugs (ONs) Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Oligonucleotide Drugs (ONs) Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of ASO
Table 4. Major Players of siRNA
Table 5. Major Players of Other
Table 6. Global Oligonucleotide Drugs (ONs) Sales by Type (2017-2022) & (K Units)
Table 7. Global Oligonucleotide Drugs (ONs) Sales Market Share by Type (2017-2022)
Table 8. Global Oligonucleotide Drugs (ONs) Revenue by Type (2017-2022) & ($ million)
Table 9. Global Oligonucleotide Drugs (ONs) Revenue Market Share by Type (2017-2022)
Table 10. Global Oligonucleotide Drugs (ONs) Sale Price by Type (2017-2022) & (US$/Unit)
Table 11. Global Oligonucleotide Drugs (ONs) Sales by Application (2017-2022) & (K Units)
Table 12. Global Oligonucleotide Drugs (ONs) Sales Market Share by Application (2017-2022)
Table 13. Global Oligonucleotide Drugs (ONs) Revenue by Application (2017-2022)
Table 14. Global Oligonucleotide Drugs (ONs) Revenue Market Share by Application (2017-2022)
Table 15. Global Oligonucleotide Drugs (ONs) Sale Price by Application (2017-2022) & (US$/Unit)
Table 16. Global Oligonucleotide Drugs (ONs) Sales by Company (2020-2022) & (K Units)
Table 17. Global Oligonucleotide Drugs (ONs) Sales Market Share by Company (2020-2022)
Table 18. Global Oligonucleotide Drugs (ONs) Revenue by Company (2020-2022) ($ Millions)
Table 19. Global Oligonucleotide Drugs (ONs) Revenue Market Share by Company (2020-2022)
Table 20. Global Oligonucleotide Drugs (ONs) Sale Price by Company (2020-2022) & (US$/Unit)
Table 21. Key Manufacturers Oligonucleotide Drugs (ONs) Producing Area Distribution and Sales Area
Table 22. Players Oligonucleotide Drugs (ONs) Products Offered
Table 23. Oligonucleotide Drugs (ONs) Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Oligonucleotide Drugs (ONs) Sales by Geographic Region (2017-2022) & (K Units)
Table 27. Global Oligonucleotide Drugs (ONs) Sales Market Share Geographic Region (2017-2022)
Table 28. Global Oligonucleotide Drugs (ONs) Revenue by Geographic Region (2017-2022) & ($ millions)
Table 29. Global Oligonucleotide Drugs (ONs) Revenue Market Share by Geographic Region (2017-2022)
Table 30. Global Oligonucleotide Drugs (ONs) Sales by Country/Region (2017-2022) & (K Units)
Table 31. Global Oligonucleotide Drugs (ONs) Sales Market Share by Country/Region (2017-2022)
Table 32. Global Oligonucleotide Drugs (ONs) Revenue by Country/Region (2017-2022) & ($ millions)
Table 33. Global Oligonucleotide Drugs (ONs) Revenue Market Share by Country/Region (2017-2022)
Table 34. Americas Oligonucleotide Drugs (ONs) Sales by Country (2017-2022) & (K Units)
Table 35. Americas Oligonucleotide Drugs (ONs) Sales Market Share by Country (2017-2022)
Table 36. Americas Oligonucleotide Drugs (ONs) Revenue by Country (2017-2022) & ($ Millions)
Table 37. Americas Oligonucleotide Drugs (ONs) Revenue Market Share by Country (2017-2022)
Table 38. Americas Oligonucleotide Drugs (ONs) Sales by Type (2017-2022) & (K Units)
Table 39. Americas Oligonucleotide Drugs (ONs) Sales Market Share by Type (2017-2022)
Table 40. Americas Oligonucleotide Drugs (ONs) Sales by Application (2017-2022) & (K Units)
Table 41. Americas Oligonucleotide Drugs (ONs) Sales Market Share by Application (2017-2022)
Table 42. APAC Oligonucleotide Drugs (ONs) Sales by Region (2017-2022) & (K Units)
Table 43. APAC Oligonucleotide Drugs (ONs) Sales Market Share by Region (2017-2022)
Table 44. APAC Oligonucleotide Drugs (ONs) Revenue by Region (2017-2022) & ($ Millions)
Table 45. APAC Oligonucleotide Drugs (ONs) Revenue Market Share by Region (2017-2022)
Table 46. APAC Oligonucleotide Drugs (ONs) Sales by Type (2017-2022) & (K Units)
Table 47. APAC Oligonucleotide Drugs (ONs) Sales Market Share by Type (2017-2022)
Table 48. APAC Oligonucleotide Drugs (ONs) Sales by Application (2017-2022) & (K Units)
Table 49. APAC Oligonucleotide Drugs (ONs) Sales Market Share by Application (2017-2022)
Table 50. Europe Oligonucleotide Drugs (ONs) Sales by Country (2017-2022) & (K Units)
Table 51. Europe Oligonucleotide Drugs (ONs) Sales Market Share by Country (2017-2022)
Table 52. Europe Oligonucleotide Drugs (ONs) Revenue by Country (2017-2022) & ($ Millions)
Table 53. Europe Oligonucleotide Drugs (ONs) Revenue Market Share by Country (2017-2022)
Table 54. Europe Oligonucleotide Drugs (ONs) Sales by Type (2017-2022) & (K Units)
Table 55. Europe Oligonucleotide Drugs (ONs) Sales Market Share by Type (2017-2022)
Table 56. Europe Oligonucleotide Drugs (ONs) Sales by Application (2017-2022) & (K Units)
Table 57. Europe Oligonucleotide Drugs (ONs) Sales Market Share by Application (2017-2022)
Table 58. Middle East & Africa Oligonucleotide Drugs (ONs) Sales by Country (2017-2022) & (K Units)
Table 59. Middle East & Africa Oligonucleotide Drugs (ONs) Sales Market Share by Country (2017-2022)
Table 60. Middle East & Africa Oligonucleotide Drugs (ONs) Revenue by Country (2017-2022) & ($ Millions)
Table 61. Middle East & Africa Oligonucleotide Drugs (ONs) Revenue Market Share by Country (2017-2022)
Table 62. Middle East & Africa Oligonucleotide Drugs (ONs) Sales by Type (2017-2022) & (K Units)
Table 63. Middle East & Africa Oligonucleotide Drugs (ONs) Sales Market Share by Type (2017-2022)
Table 64. Middle East & Africa Oligonucleotide Drugs (ONs) Sales by Application (2017-2022) & (K Units)
Table 65. Middle East & Africa Oligonucleotide Drugs (ONs) Sales Market Share by Application (2017-2022)
Table 66. Key Market Drivers & Growth Opportunities of Oligonucleotide Drugs (ONs)
Table 67. Key Market Challenges & Risks of Oligonucleotide Drugs (ONs)
Table 68. Key Industry Trends of Oligonucleotide Drugs (ONs)
Table 69. Oligonucleotide Drugs (ONs) Raw Material
Table 70. Key Suppliers of Raw Materials
Table 71. Oligonucleotide Drugs (ONs) Distributors List
Table 72. Oligonucleotide Drugs (ONs) Customer List
Table 73. Global Oligonucleotide Drugs (ONs) Sales Forecast by Region (2023-2028) & (K Units)
Table 74. Global Oligonucleotide Drugs (ONs) Sales Market Forecast by Region
Table 75. Global Oligonucleotide Drugs (ONs) Revenue Forecast by Region (2023-2028) & ($ millions)
Table 76. Global Oligonucleotide Drugs (ONs) Revenue Market Share Forecast by Region (2023-2028)
Table 77. Americas Oligonucleotide Drugs (ONs) Sales Forecast by Country (2023-2028) & (K Units)
Table 78. Americas Oligonucleotide Drugs (ONs) Revenue Forecast by Country (2023-2028) & ($ millions)
Table 79. APAC Oligonucleotide Drugs (ONs) Sales Forecast by Region (2023-2028) & (K Units)
Table 80. APAC Oligonucleotide Drugs (ONs) Revenue Forecast by Region (2023-2028) & ($ millions)
Table 81. Europe Oligonucleotide Drugs (ONs) Sales Forecast by Country (2023-2028) & (K Units)
Table 82. Europe Oligonucleotide Drugs (ONs) Revenue Forecast by Country (2023-2028) & ($ millions)
Table 83. Middle East & Africa Oligonucleotide Drugs (ONs) Sales Forecast by Country (2023-2028) & (K Units)
Table 84. Middle East & Africa Oligonucleotide Drugs (ONs) Revenue Forecast by Country (2023-2028) & ($ millions)
Table 85. Global Oligonucleotide Drugs (ONs) Sales Forecast by Type (2023-2028) & (K Units)
Table 86. Global Oligonucleotide Drugs (ONs) Sales Market Share Forecast by Type (2023-2028)
Table 87. Global Oligonucleotide Drugs (ONs) Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 88. Global Oligonucleotide Drugs (ONs) Revenue Market Share Forecast by Type (2023-2028)
Table 89. Global Oligonucleotide Drugs (ONs) Sales Forecast by Application (2023-2028) & (K Units)
Table 90. Global Oligonucleotide Drugs (ONs) Sales Market Share Forecast by Application (2023-2028)
Table 91. Global Oligonucleotide Drugs (ONs) Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 92. Global Oligonucleotide Drugs (ONs) Revenue Market Share Forecast by Application (2023-2028)
Table 93. Novartis Basic Information, Oligonucleotide Drugs (ONs) Manufacturing Base, Sales Area and Its Competitors
Table 94. Novartis Oligonucleotide Drugs (ONs) Product Offered
Table 95. Novartis Oligonucleotide Drugs (ONs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 96. Novartis Main Business
Table 97. Novartis Latest Developments
Table 98. Ionis Basic Information, Oligonucleotide Drugs (ONs) Manufacturing Base, Sales Area and Its Competitors
Table 99. Ionis Oligonucleotide Drugs (ONs) Product Offered
Table 100. Ionis Oligonucleotide Drugs (ONs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 101. Ionis Main Business
Table 102. Ionis Latest Developments
Table 103. Nippon Shinyaku Basic Information, Oligonucleotide Drugs (ONs) Manufacturing Base, Sales Area and Its Competitors
Table 104. Nippon Shinyaku Oligonucleotide Drugs (ONs) Product Offered
Table 105. Nippon Shinyaku Oligonucleotide Drugs (ONs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 106. Nippon Shinyaku Main Business
Table 107. Nippon Shinyaku Latest Developments
Table 108. Alnylam Basic Information, Oligonucleotide Drugs (ONs) Manufacturing Base, Sales Area and Its Competitors
Table 109. Alnylam Oligonucleotide Drugs (ONs) Product Offered
Table 110. Alnylam Oligonucleotide Drugs (ONs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 111. Alnylam Main Business
Table 112. Alnylam Latest Developments
Table 113. Sarepta Therapeutics Basic Information, Oligonucleotide Drugs (ONs) Manufacturing Base, Sales Area and Its Competitors
Table 114. Sarepta Therapeutics Oligonucleotide Drugs (ONs) Product Offered
Table 115. Sarepta Therapeutics Oligonucleotide Drugs (ONs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 116. Sarepta Therapeutics Main Business
Table 117. Sarepta Therapeutics Latest Developments
Table 118. MiNA Therapeutics Basic Information, Oligonucleotide Drugs (ONs) Manufacturing Base, Sales Area and Its Competitors
Table 119. MiNA Therapeutics Oligonucleotide Drugs (ONs) Product Offered
Table 120. MiNA Therapeutics Oligonucleotide Drugs (ONs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 121. MiNA Therapeutics Main Business
Table 122. MiNA Therapeutics Latest Developments
Table 123. BioNTech Basic Information, Oligonucleotide Drugs (ONs) Manufacturing Base, Sales Area and Its Competitors
Table 124. BioNTech Oligonucleotide Drugs (ONs) Product Offered
Table 125. BioNTech Oligonucleotide Drugs (ONs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 126. BioNTech Main Business
Table 127. BioNTech Latest Developments
Table 128. Moderna Basic Information, Oligonucleotide Drugs (ONs) Manufacturing Base, Sales Area and Its Competitors
Table 129. Moderna Oligonucleotide Drugs (ONs) Product Offered
Table 130. Moderna Oligonucleotide Drugs (ONs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 131. Moderna Main Business
Table 132. Moderna Latest Developments
List of Figures
Figure 1. Picture of Oligonucleotide Drugs (ONs)
Figure 2. Oligonucleotide Drugs (ONs) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Oligonucleotide Drugs (ONs) Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Oligonucleotide Drugs (ONs) Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Oligonucleotide Drugs (ONs) Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of ASO
Figure 10. Product Picture of siRNA
Figure 11. Product Picture of Other
Figure 12. Global Oligonucleotide Drugs (ONs) Sales Market Share by Type in 2021
Figure 13. Global Oligonucleotide Drugs (ONs) Revenue Market Share by Type (2017-2022)
Figure 14. Oligonucleotide Drugs (ONs) Consumed in Cardiovascular Diseases
Figure 15. Global Oligonucleotide Drugs (ONs) Market: Cardiovascular Diseases (2017-2022) & (K Units)
Figure 16. Oligonucleotide Drugs (ONs) Consumed in Hepatitis B
Figure 17. Global Oligonucleotide Drugs (ONs) Market: Hepatitis B (2017-2022) & (K Units)
Figure 18. Oligonucleotide Drugs (ONs) Consumed in Hypertension
Figure 19. Global Oligonucleotide Drugs (ONs) Market: Hypertension (2017-2022) & (K Units)
Figure 20. Oligonucleotide Drugs (ONs) Consumed in Other
Figure 21. Global Oligonucleotide Drugs (ONs) Market: Other (2017-2022) & (K Units)
Figure 22. Global Oligonucleotide Drugs (ONs) Sales Market Share by Application (2017-2022)
Figure 23. Global Oligonucleotide Drugs (ONs) Revenue Market Share by Application in 2021
Figure 24. Oligonucleotide Drugs (ONs) Revenue Market by Company in 2021 ($ Million)
Figure 25. Global Oligonucleotide Drugs (ONs) Revenue Market Share by Company in 2021
Figure 26. Global Oligonucleotide Drugs (ONs) Sales Market Share by Geographic Region (2017-2022)
Figure 27. Global Oligonucleotide Drugs (ONs) Revenue Market Share by Geographic Region in 2021
Figure 28. Global Oligonucleotide Drugs (ONs) Sales Market Share by Region (2017-2022)
Figure 29. Global Oligonucleotide Drugs (ONs) Revenue Market Share by Country/Region in 2021
Figure 30. Americas Oligonucleotide Drugs (ONs) Sales 2017-2022 (K Units)
Figure 31. Americas Oligonucleotide Drugs (ONs) Revenue 2017-2022 ($ Millions)
Figure 32. APAC Oligonucleotide Drugs (ONs) Sales 2017-2022 (K Units)
Figure 33. APAC Oligonucleotide Drugs (ONs) Revenue 2017-2022 ($ Millions)
Figure 34. Europe Oligonucleotide Drugs (ONs) Sales 2017-2022 (K Units)
Figure 35. Europe Oligonucleotide Drugs (ONs) Revenue 2017-2022 ($ Millions)
Figure 36. Middle East & Africa Oligonucleotide Drugs (ONs) Sales 2017-2022 (K Units)
Figure 37. Middle East & Africa Oligonucleotide Drugs (ONs) Revenue 2017-2022 ($ Millions)
Figure 38. Americas Oligonucleotide Drugs (ONs) Sales Market Share by Country in 2021
Figure 39. Americas Oligonucleotide Drugs (ONs) Revenue Market Share by Country in 2021
Figure 40. United States Oligonucleotide Drugs (ONs) Revenue Growth 2017-2022 ($ Millions)
Figure 41. Canada Oligonucleotide Drugs (ONs) Revenue Growth 2017-2022 ($ Millions)
Figure 42. Mexico Oligonucleotide Drugs (ONs) Revenue Growth 2017-2022 ($ Millions)
Figure 43. Brazil Oligonucleotide Drugs (ONs) Revenue Growth 2017-2022 ($ Millions)
Figure 44. APAC Oligonucleotide Drugs (ONs) Sales Market Share by Region in 2021
Figure 45. APAC Oligonucleotide Drugs (ONs) Revenue Market Share by Regions in 2021
Figure 46. China Oligonucleotide Drugs (ONs) Revenue Growth 2017-2022 ($ Millions)
Figure 47. Japan Oligonucleotide Drugs (ONs) Revenue Growth 2017-2022 ($ Millions)
Figure 48. South Korea Oligonucleotide Drugs (ONs) Revenue Growth 2017-2022 ($ Millions)
Figure 49. Southeast Asia Oligonucleotide Drugs (ONs) Revenue Growth 2017-2022 ($ Millions)
Figure 50. India Oligonucleotide Drugs (ONs) Revenue Growth 2017-2022 ($ Millions)
Figure 51. Australia Oligonucleotide Drugs (ONs) Revenue Growth 2017-2022 ($ Millions)
Figure 52. Europe Oligonucleotide Drugs (ONs) Sales Market Share by Country in 2021
Figure 53. Europe Oligonucleotide Drugs (ONs) Revenue Market Share by Country in 2021
Figure 54. Germany Oligonucleotide Drugs (ONs) Revenue Growth 2017-2022 ($ Millions)
Figure 55. France Oligonucleotide Drugs (ONs) Revenue Growth 2017-2022 ($ Millions)
Figure 56. UK Oligonucleotide Drugs (ONs) Revenue Growth 2017-2022 ($ Millions)
Figure 57. Italy Oligonucleotide Drugs (ONs) Revenue Growth 2017-2022 ($ Millions)
Figure 58. Russia Oligonucleotide Drugs (ONs) Revenue Growth 2017-2022 ($ Millions)
Figure 59. Middle East & Africa Oligonucleotide Drugs (ONs) Sales Market Share by Country in 2021
Figure 60. Middle East & Africa Oligonucleotide Drugs (ONs) Revenue Market Share by Country in 2021
Figure 61. Egypt Oligonucleotide Drugs (ONs) Revenue Growth 2017-2022 ($ Millions)
Figure 62. South Africa Oligonucleotide Drugs (ONs) Revenue Growth 2017-2022 ($ Millions)
Figure 63. Israel Oligonucleotide Drugs (ONs) Revenue Growth 2017-2022 ($ Millions)
Figure 64. Turkey Oligonucleotide Drugs (ONs) Revenue Growth 2017-2022 ($ Millions)
Figure 65. GCC Country Oligonucleotide Drugs (ONs) Revenue Growth 2017-2022 ($ Millions)
Figure 66. Manufacturing Cost Structure Analysis of Oligonucleotide Drugs (ONs) in 2021
Figure 67. Manufacturing Process Analysis of Oligonucleotide Drugs (ONs)
Figure 68. Industry Chain Structure of Oligonucleotide Drugs (ONs)
Figure 69. Channels of Distribution
Figure 70. Distributors Profiles
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets